Bird 2000.

Study characteristics
Methods	Design: parallel Duration: 8 weeks Assessment: baseline and post‐intervention Countries: UK, Ireland, Germany, Italy, and Belgium
Participants	Pain condition: RA Population: adults with RA and depression Minimum pain intensity: NR Inclusion criteria Aged 18‐70 RA for > 1 year Diagnosis of mild, moderate, or severe depression Had a total MADRS score of ≥ 16 Exclusion criteria Severe comorbid physical conditions Total participants randomised: 191 Age in years (mean): 54.8 Gender: 150/191 were female Pain duration in years (mean, SD): NR
Interventions	Paroxetine 20‐40 mg n = 94 SSRI Flexible dosing based on efficacy Amitriptyline 75‐150 mg n = 97 TCA Flexible dosing based on efficacy
Outcomes	Mood PGIC AEs SAEs Withdrawal
Missing data methods	ITT but imputation method not specified
Funding source	Pharmaceutical ‐ educational grant from SmithKline Beecham
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information given
Allocation concealment (selection bias)	Unclear risk	No information given
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded ‐ double‐dummy dosing schedule
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	States ITT but no information regarding imputation method given Attrition Total: 37/191 (19.4%) Paroxetine 20‐40 mg: 18/95 (18.9%) Amitriptyline 75‐150 mg: 20/105 (19.0%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified.